SH3KBP1 (SH3 domain-containing kinase-binding protein 1), also known as CIN85 or CD2BP3. is an adapter protein involved in regulating intracellular signaling pathways. It contains multiple protein interaction domains, including three SH3 domains, a proline-rich region, and a coiled-coil domain, enabling interactions with diverse partners like Cbl, CD2. PI3K, and endocytic proteins. SH3KBP1 plays critical roles in receptor tyrosine kinase (RTK) endocytosis, apoptosis, cytoskeletal remodeling, and cell migration. Its function is closely linked to cancer progression, as it modulates EGFR trafficking and downstream signaling. Overexpression of SH3KBP1 has been observed in glioblastoma and linked to enhanced tumor cell invasion, while its downregulation in breast cancer correlates with poor prognosis, suggesting context-dependent roles. In neurological disorders, SH3KBP1 interacts with proteins like HIP1R and ALIX, influencing synaptic vesicle recycling and neuronal connectivity, with implications in Alzheimer’s disease. Antibodies targeting SH3KBP1 are widely used in research to study its expression, localization, and post-translational modifications (e.g., phosphorylation at Ser230) via techniques like Western blot, immunohistochemistry, and co-immunoprecipitation. Challenges include cross-reactivity with isoforms and ensuring specificity due to structural homology among SH3 domain-containing proteins. Validated antibodies are crucial for elucidating SH3KBP1’s dual roles in oncogenesis and neurobiology, highlighting its potential as a therapeutic target or biomarker.